Advanced Medical Solutions Group PLC (GB:AMS)
LSE:AMS
Top Page
Advanced Medical Solutions
(LSE:AMS)
Select Model
Select Model
Rating:56Neutral
Price Target:
207.00 p
▼(-3.72% Downside)
Action:ReiteratedDate:03/20/26
The score is mainly driven by mixed financial performance: improving 2025 revenue growth and cash generation, but materially weaker margins/returns versus prior peaks and higher leverage. Technical indicators point to soft momentum with the price below key moving averages. Valuation further pressures the score due to a high P/E, with only modest support from the dividend yield.
Positive Factors
Revenue re-acceleration
Sustained revenue re-acceleration indicates recovering demand and improved commercial execution. Over the next 2–6 months stronger top-line momentum can expand operating leverage, support reinvestment in growth initiatives, and provide a base for margin recovery if cost control continues.
Negative Factors
Compressed profitability
Material margin erosion versus prior peaks signals structural pressure on profitability. Lower operating and net margins reduce retained earnings and free cash conversion, constrain reinvestment capacity, and leave the business more vulnerable to sustained cost inflation or pricing pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue re-acceleration
Sustained revenue re-acceleration indicates recovering demand and improved commercial execution. Over the next 2–6 months stronger top-line momentum can expand operating leverage, support reinvestment in growth initiatives, and provide a base for margin recovery if cost control continues.
Read all positive factors
Advanced Medical Solutions (AMS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£415.04M
Dividend Yield1.25%
Average Volume (3M)800.99K
Price to Earnings (P/E)47.2
Beta (1Y)1.38
Revenue Growth68.03%
EPS Growth-18.27%
CountryUK
Employees1,500
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.02
Shares Outstanding219,590,320
10 Day Avg. Volume1,242,574
30 Day Avg. Volume800,991
Financial Highlights & Ratios
PEG Ratio1.19
Price to Book (P/B)1.82
Price to Sales (P/S)2.05
P/FCF Ratio21.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£300.00Price Target Upside39.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.13
Revenue Forecast (FY)£245.72M
Advanced Medical Solutions Business Overview & Revenue Model
Company Description
Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, France, rest of Europe, the Uni...
How the Company Makes Money
null...
Advanced Medical Solutions Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 228.94M | 177.52M | 126.21M | 124.33M | 108.60M |
| Gross Profit | 108.78M | 82.77M | 70.14M | 68.62M | 56.12M |
| EBITDA | 43.39M | 29.68M | 31.40M | 34.94M | 31.55M |
| Net Income | 9.95M | 7.09M | 15.89M | 20.41M | 17.48M |
Balance Sheet | |||||
| Total Assets | 394.77M | 389.00M | 289.17M | 281.09M | 249.51M |
| Cash, Cash Equivalents and Short-Term Investments | 18.02M | 17.04M | 60.16M | 82.26M | 72.97M |
| Total Debt | 81.52M | 89.65M | 9.14M | 9.75M | 9.86M |
| Total Liabilities | 134.67M | 147.48M | 44.97M | 44.47M | 36.83M |
| Stockholders Equity | 258.79M | 240.78M | 244.20M | 236.62M | 212.68M |
Cash Flow | |||||
| Free Cash Flow | 21.39M | 12.67M | 2.50M | 17.12M | 23.95M |
| Operating Cash Flow | 28.75M | 16.73M | 12.35M | 27.08M | 30.41M |
| Investing Cash Flow | -13.54M | -67.15M | -20.27M | -12.70M | -6.41M |
| Financing Cash Flow | -14.92M | 5.48M | -13.62M | -5.70M | -4.41M |
Advanced Medical Solutions Technical Analysis
Negative
215.00
Price Trends
208.84
Negative
212.16
Negative
211.21
Negative
Market Momentum
-4.54
Negative
37.31
Neutral
21.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AMS, the sentiment is Negative. The current price of 215 is above the 20-day moving average (MA) of 196.89, above the 50-day MA of 208.84, and above the 200-day MA of 211.21, indicating a bearish trend. The MACD of -4.54 indicates Negative momentum. The RSI at 37.31 is Neutral, neither overbought nor oversold. The STOCH value of 21.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AMS.
Advanced Medical Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £177.35M | 12.60 | 23.64% | 3.48% | 10.80% | 1.75% | |
68 Neutral | £242.40M | 39.29 | 10.14% | 3.40% | 17.95% | -54.68% | |
67 Neutral | £4.26B | 37.08 | 10.53% | 2.11% | 4.18% | 37.65% | |
56 Neutral | £415.04M | 47.21 | 3.69% | 1.25% | 68.03% | -18.27% | |
55 Neutral | £267.37M | -2.25 | 12.82% | ― | 1231.50% | ― | |
55 Neutral | £574.59M | 40.77 | 2.22% | 1.37% | 6.95% | -34.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GB:AMS
Advanced Medical Solutions
191.80
-37.29
-16.28%
GB:NIOX
Circassia Pharmaceuticals
58.00
-16.64
-22.30%
GB:CTEC
ConvaTec
218.60
-33.50
-13.29%
GB:PRTC
PureTech Health
110.00
-33.60
-23.40%
GB:SPI
Spire Healthcare
142.80
-32.53
-18.55%
GB:TSTL
Tristel
370.00
86.20
30.38%
Advanced Medical Solutions Corporate Events
Business Operations and StrategyDividendsFinancial Disclosures
Advanced Medical Solutions posts record 2025 results as Peters acquisition powers growth
Positive
Mar 18, 2026
Advanced Medical Solutions reported record 2025 results, with group revenue rising 29% to £228.9m and adjusted EBITDA up 24% to £49.9m, driven by strong organic growth and the first full-year contribution from the Peters Surgical acquisi...
Business Operations and StrategyRegulatory Filings and Compliance
Advanced Medical Solutions Expands Share Scheme Capacity to Support Growth and Incentives
Positive
Mar 6, 2026
Advanced Medical Solutions Group has updated the market on its block admission arrangements for a range of employee and executive share incentive schemes. The filing details the additional ordinary shares now available under its employee share pur...
Regulatory Filings and Compliance
Advanced Medical Solutions Updates Share Capital and Voting Rights
Neutral
Mar 2, 2026
Advanced Medical Solutions Group has confirmed that its issued share capital as of 27 February 2026 consists of 219,590,310 ordinary shares of 5p each, all carrying voting rights and with no shares held in treasury. This updated share count serves...
Regulatory Filings and Compliance
Advanced Medical Solutions Confirms Current Share Capital and Voting Rights
Neutral
Jan 30, 2026
Advanced Medical Solutions Group has confirmed that its issued share capital as of 30 January 2026 consists of 219,584,690 ordinary shares of 5p each, all carrying voting rights and with no shares held in treasury. This figure sets the reference p...
Business Operations and StrategyFinancial Disclosures
Advanced Medical Solutions lifts 2025 revenues as surgical products drive growth
Positive
Jan 15, 2026
Advanced Medical Solutions Group expects to report 2025 revenues of about £228.5 million, up from £177.5 million a year earlier, and EBITDA of £49.5–£50 million, with the board confident of meeting market expectations. Gr...
Regulatory Filings and Compliance
Advanced Medical Solutions Confirms Total Voting Rights at Year-End 2025
Neutral
Jan 2, 2026
Advanced Medical Solutions Group plc has confirmed that as of 31 December 2025 its issued share capital consists of 219,556,971 ordinary shares of 5p each, all carrying voting rights, with no shares held in treasury. This updated total voting righ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.